Semus Wealth Partners LLC Purchases 1,823 Shares of Merck & Co., Inc. $MRK

Semus Wealth Partners LLC grew its position in Merck & Co., Inc. (NYSE:MRK) by 36.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 6,862 shares of the company’s stock after purchasing an additional 1,823 shares during the quarter. Semus Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $543,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Little House Capital LLC boosted its position in Merck & Co., Inc. by 1.2% during the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock valued at $1,998,000 after purchasing an additional 308 shares during the last quarter. Longfellow Investment Management Co. LLC increased its position in shares of Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after purchasing an additional 3,282 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its stake in shares of Merck & Co., Inc. by 9.8% during the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after purchasing an additional 79,529 shares in the last quarter. Amplius Wealth Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 117.4% in the 2nd quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock valued at $488,000 after buying an additional 3,329 shares during the last quarter. Finally, Diversified Trust Co boosted its holdings in shares of Merck & Co., Inc. by 3.8% in the 2nd quarter. Diversified Trust Co now owns 189,651 shares of the company’s stock valued at $15,013,000 after buying an additional 6,930 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Up 0.0%

MRK stock opened at $92.94 on Tuesday. The stock has a market cap of $230.69 billion, a price-to-earnings ratio of 14.32, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34. The company has a fifty day moving average price of $85.43 and a two-hundred day moving average price of $82.43. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $105.07. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.36 by $0.22. The business had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc.’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Scotiabank started coverage on shares of Merck & Co., Inc. in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $105.00 target price on the stock. Finally, Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the company an “equal weight” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $104.50.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP David Michael Williams sold 8,614 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the transaction, the executive vice president directly owned 24,578 shares in the company, valued at approximately $2,054,475.02. This represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.